Review article

THE USE OF ORAL HYPOGLYCEMIC AGENTS IN CHRONIC KIDNEY DISEASE

KRISTINA BLASLOV orcid.org/0000-0002-9747-8742 ; Merkur University Hospital, Zagreb, Croatia
JELENA MARINKOVIĆ ; Sestre milosrdnice University Hospital Center, Mladen Sekso Clinical Department of Endocrinology, Dermatovenereology, Allergology and Immunology Clinical Unit, Diabetes and Metabolic Diseases, Zagreb, Croatia
IVAN KRULJAC ; Sestre milosrdnice University Hospital Center, Mladen Sekso Clinical Department of Endocrinology, Dermatovenereology, Allergology and Immunology Clinical Unit, Diabetes and Metabolic Diseases, Zagreb, Croatia

Abstract

It is estimated that 200 million people suffer from chronic kidney disease (CKD) worldwide. Diabetes mellitus and associated disorders of hypertension and arteriosclerosis are the most common causes. Appropriate glucoregulation may postpone its onset and/or progression. Although insulin is the most commonly used antidiabetic agent in CKD patients, nowadays there is a wide spectrum of oral antidiabetic agents that can be used safely and effectively across different stages of CKD.

Keywords

diabetes mellitus; chronic kidney disease; oral hypoglycemic agents

Hrčak ID:

193696

URI

https://hrcak.srce.hr/193696

Publication date:

13.2.2018.

Article data in other languages: croatian

Visits: 1.385 *